

Combination for
**SYNERGISTIC
ACTION**



Now Available

IMPUROSE-A 10/20

Rosuvastatin 10/20 mg + Aspirin 75 mg Capsules

IMPUROSE-C 10/20

Rosuvastatin 10/20 mg + Clopidogrel 75 mg Capsules

Also Available

IMPUROSE-AC 10/20

Rosuvastatin 10/20 mg + Aspirin 75 mg + Clopidogrel 75 mg Capsules

IMPUROSE-A/C/AC

Rosuvastatin 10/20 mg + Aspirin 75 mg Capsules /
Rosuvastatin 10/20 mg + Clopidogrel 75 mg Capsules /
Rosuvastatin 10/20 mg + Aspirin 75 mg + Clopidogrel 75 mg Capsules

BACKGROUND

- The burden of Acute coronary syndrome (ACS) in India is one of the highest in the world as it includes acute Myocardial infarction (MI) and unstable angina.
- Following an ACS, the chances of recurrent coronary events are higher than that of a stable coronary disease. The major contributing factor relating to ACS are dyslipidemia and atherosclerosis of coronary arteries.
- A study called CREATE, involving 20,937 patients suggested that Indian patients with ACS have the higher rate of STEMI than patients in developed countries.
- DAPT (Aspirin, Clopidogrel) combined with rosuvastatin effectively reduce the risk of recurrent ischemic stroke without increasing adverse events such as bleeding.

DESCRIPTION

IMPUROSE-A/C/AC: This combination is used in the primary prevention and secondary prevention of Coronary Artery Disease.

The strengths available are:

IMPUROSE-A 10/20: Rosuvastatin 10/20 mg + Aspirin 75 mg Capsules

IMPUROSE-C 10/20: Rosuvastatin 10/20 mg + Clopidogrel 75 mg Capsules

IMPUROSE-AC 10/20: Rosuvastatin 10/20 mg + Aspirin 75 mg + Clopidogrel 75 mg Capsules

INDICATION

IMPUROSE-A/C/AC: It is indicated in primary as well as secondary prevention of atherothrombosis, acute coronary syndrome, non-ST elevation myocardial infarction, stroke and angina.

MECHANISM OF ACTION

- **Rosuvastatin** is a competitive inhibitor of HMG-CoA reductase. HMG-CoA reductase catalyses the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.
- **Aspirin** works by irreversibly inhibiting the enzyme cyclo-oxygenase (COX-1) which reduces thromboxane synthesis. Thromboxane is required to facilitate platelet aggregation and to stimulate further platelet activation.
- Clopidogrel acts by inhibiting the adenosine diphosphate receptor on platelet cell membranes in order to inhibit platelet activation and aggregation.

DOSAGE AND ADMINISTRATION

IMPUROSE-A/C/AC: One tablet a day or as directed by the Doctor.

STEMI: ST-segment Elevation Myocardial Infarction

DAPT: Dual Antiplatelet Therapy




References:

1. Lancet. 2008 Apr 26;371(9622):1435-42

2. Clinics (Sao Paulo). 2023 Jan-Dec; 78: 100171.

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

 I am: _____
 Call me on: _____
 Mail me at: _____

©2023 All rights reserved, La Renon Healthcare Private Limited